Unicycive Therapeutics logo
Unicycive Therapeutics
UNCY | NASDAQ
Chart Builder DCF Calculator
$3.70
+$0.15 (+4.23%)
At close: Nov 16, 2026, 4:00 PM ET
$3.70
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:34 PM ET

Unicycive Therapeutics Company Profile

Company profile explained

Company Profile

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Key Executives

Name Position
Shalabh K. Gupta Founder, Chairman, Chief Executive Officer & President
John W. Townsend Chief Financial Officer
Douglas Jermasek Executive Vice President of Corporate Strategy
Pramod Gupta Executive Vice President of Pharmaceutical and Business Operations

Latest SEC Filings

Date Type Title
Oct 29, 2026 4 Filing
Oct 01, 2026 3 Filing
Sep 29, 2026 8-K Current Report
Sep 28, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 8-K Current Report
Aug 12, 2026 10-Q Quarterly Report
Jul 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 28, 2026 4/A [Amend] Filing
View All SEC Filings ➞
Unicycive Therapeutics
Unicycive Therapeutics logo
Country United States
IPO Date Jul 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Shalabh K. Gupta

Contact Details

1975 West El Camino Real Mountain View, California 94040 United States

Stock Details

Ticker Symbol UNCY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001766140
CUSIP Number 90466Y202
ISIN Number US90466Y2028
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.